HGH vs IGF-1
Human growth hormone (HGH) and insulin-like growth factor 1 (IGF-1) form the somatotropic axis, where GH stimulates hepatic IGF-1 production. However, their pharmacological profiles diverge substantially — HGH acts indirectly through receptor-mediated signaling, while IGF-1 provides direct anabolic effects at peripheral tissues.
Mechanism of Action
Section titled “Mechanism of Action”HGH: Growth Hormone Receptor Agonism
Section titled “HGH: Growth Hormone Receptor Agonism”HGH activates the growth hormone receptor (GHR), a transmembrane receptor of the cytokine receptor superfamily:
- JAK2/STAT5 signaling: Primary pathway for hepatic IGF-1 gene transcription
- MAPK/ERK pathway: Mediates mitogenic effects on chondrocytes and osteoblasts
- PI3K/Akt pathway: Lipolytic effects in adipose tissue, insulin resistance
- Direct lipolysis: HGH directly activates hormone-sensitive lipase in adipocytes
- Insulin antagonism: Competes with insulin for post-receptor signaling
HGH effects are both IGF-1-dependent (hepatic) and IGF-1-independent (direct tissue effects).
IGF-1: IGF-1R Tyrosine Kinase Activation
Section titled “IGF-1: IGF-1R Tyrosine Kinase Activation”IGF-1 activates the IGF-1 receptor (IGF-1R), a heterotetrameric tyrosine kinase:
- PI3K/Akt/mTOR: Primary anabolic signaling cascade
- MAPK/ERK: Mitogenic and differentiation signaling
- Structural homology: ~60% sequence identity to insulin, cross-reacts with insulin receptor at high concentrations
- Local vs circulating: Acts in autocrine/paracrine fashion or as an endocrine hormone
- No lipolytic effect: Unlike HGH, IGF-1 does not directly mobilize lipids
IGF-1 bypasses the liver-dependent step, providing direct anabolic signaling at muscle, bone, and connective tissue.
Pulsatility vs Constant Exposure
Section titled “Pulsatility vs Constant Exposure”| Parameter | HGH | IGF-1 |
|---|---|---|
| Secretion pattern | Pulsatile (6-12 pulses/day) | Relatively constant |
| Peak:trough ratio | 10-20x | <2x |
| Circadian rhythm | Major peak during sleep | Minimal variation |
| Feedback regulation | IGF-1 + GH itself | GH-dependent |
| Receptor desensitization | Protected by pulsatility | More susceptible |
Clinical Significance of Pulsatility
Section titled “Clinical Significance of Pulsatility”GH pulsatility is physiologically important:
- Pulsatile HGH: Better tolerated, more physiological, lower IGF-1 spikes
- Continuous HGH: Greater insulin resistance, more side effects, non-physiological
- IGF-1 administration: Bypasses GH pulsatility entirely — constant IGF-1 exposure
Research protocols evaluating HGH pharmacokinetics should account for pulsatile secretion patterns.
Production Sites and Bioavailability
Section titled “Production Sites and Bioavailability”HGH: Hypothalamic-Pituitary Axis
Section titled “HGH: Hypothalamic-Pituitary Axis”- Source: Somatotroph cells of anterior pituitary
- Regulation: GHRH (stimulatory) from hypothalamus, somatostatin (inhibitory)
- Molecular weight: 22 kDa (91 amino acids)
- Bioavailability: ~70% after subcutaneous injection
- Half-life: 20-30 minutes (pulsatile), up to 20 hours (bound to GHBP)
IGF-1: Hepatic and Peripheral Production
Section titled “IGF-1: Hepatic and Peripheral Production”- Source: Primarily liver (~75%), plus local production in most tissues
- Regulation: GH-dependent (hepatic), tissue-specific (local)
- Molecular weight: 7.6 kDa (70 amino acids)
- Bioavailability: Bound to IGF-binding proteins (IGFBP-1 to -6)
- Half-life: 10-15 minutes (free), 12-15 hours (IGFBP-3 bound)
| Property | HGH | IGF-1 |
|---|---|---|
| Primary source | Pituitary | Liver |
| Local production | Minimal | Widespread |
| Binding proteins | GHBP (1 binding protein) | IGFBP-1 to -6 |
| Bioavailable fraction | ~70% | ~1-2% (free IGF-1) |
| Storage | Not stored | Not stored |
Side Effects
Section titled “Side Effects”HGH Side Effects
Section titled “HGH Side Effects”| Side Effect | Mechanism | Incidence |
|---|---|---|
| Injection site reactions | Local irritation | 5-15% |
| Fluid retention | Na+ retention, GFR increase | 10-20% |
| Joint pain | Periosteal bone growth | 5-10% |
| Carpal tunnel syndrome | Fluid retention, nerve compression | 3-8% |
| Insulin resistance | Post-receptor insulin antagonism | 10-25% |
| Gynecomastia | Increased aromatization | 2-5% |
| Increased glucose | Insulin resistance | 10-20% |
IGF-1 Side Effects
Section titled “IGF-1 Side Effects”| Side Effect | Mechanism | Incidence |
|---|---|---|
| Hypoglycemia | Insulin-like effects at high doses | 10-30% |
| Injection site reactions | Local irritation | 5-10% |
| Jaw pain (acromegalic changes) | Bone growth | 3-8% |
| Headache | Intracranial pressure (rare) | 2-5% |
| Tachycardia | Cardiovascular effects | 3-5% |
| Increased tumor risk | Mitogenic signaling | Uncertain |
Key Differences
Section titled “Key Differences”IGF-1 produces more pronounced hypoglycemia due to direct insulin-like effects. HGH produces more fluid retention and insulin resistance through indirect mechanisms. Both carry theoretical concerns about mitogenic potential at supraphysiological doses.
Clinical Applications
Section titled “Clinical Applications”HGH Approved Indications
Section titled “HGH Approved Indications”- Growth hormone deficiency (pediatric and adult)
- Turner syndrome
- Prader-Willi syndrome
- Chronic kidney disease (pediatric)
- Idiopathic short stature
IGF-1 Approved Indications
Section titled “IGF-1 Approved Indications”- Severe primary IGF-1 deficiency
- Growth hormone insensitivity (Laron syndrome)
- IGF-1 gene deletion
Research Applications
Section titled “Research Applications”Both are investigated for:
- Anti-aging (controversial)
- Body composition modification
- Athletic performance enhancement
- Metabolic syndrome
- Osteoporosis
For research-grade HGH and IGF-1 analogs, see Kingston Peptides.
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | HGH | IGF-1 |
|---|---|---|
| Oral bioavailability | <5% | <5% |
| SC bioavailability | ~70% | ~50-70% |
| Onset of action | Minutes | Minutes |
| Peak effect | 2-4 hours | 1-2 hours |
| Duration | 12-24 hours | 6-12 hours |
| Dosing frequency | Daily or 3x/week | 1-2x daily |
References
Section titled “References”- Giustina A, Veldhuis JD. “Pathophysiology of the neuroregulation of growth hormone secretion.” Endocr Rev 1998;19:717-797.
- Le Roith D, et al. “The somatomedin hypothesis: 2001.” Endocr Rev 2001;22:53-74.
- Ranke MB, Wit JM. “Growth hormone — past, present and future.” Nat Rev Endocrinol 2018;14:285-300.
- Clemmons DR. “Use of mutagenesis to probe IGF-binding protein structure/function relationships.” Endocr Rev 2001;22:800-817.
- Rosenfeld RG, et al. “The role of the insulin-like growth factors and their binding proteins in growth and metabolism.” J Clin Invest 2006;116:2844-2852.